Thus, early use of GLP-1 RAs - in the setting of asthma and diabetes/metabolic syndrome - can potentially lead to better asthma outcomes, less medication burden, lower cost, and overall improvement of asthma-related quality of life measures. This evidence concerns the gene GLP1R and diabetes mellitus.